Oral sodium phenylbutyrate for hyperammonemia associated with congenital portosystemic shunt: a case report

J Pediatr Endocrinol Metab. 2020 Dec 14;34(3):407-410. doi: 10.1515/jpem-2020-0603. Print 2021 Mar 26.

Abstract

Objectives: The efficacy of sodium phenylbutyrate (SPB) for hyperammonemia associated with congenital portosystemic shunt (CPSS) remains unknown. We show the effectiveness of oral SPB.

Case presentation: Our patient had CPSS with severe hypoplasia of extrahepatic portal veins. At 9 months of age, to assess the efficacy of oral SPB, we evaluated the 24 h fluctuations of venous ammonia levels. In the first two days without SPB, ammonia levels were above 80 μmol/L for half a day. On the third and fourth days, administration of oral SPB three times a day decreased ammonia to acceptable levels, except at midnight. On the fifth day, another oral SPB administration at 8 pm decreased ammonia at midnight. Low levels of branched-chain amino acids, as well as coagulation disturbances, were observed without apparent symptoms. At 12 months of age, he showed normal psychomotor development.

Conclusions: Oral SPB may be effective for hyperammonemia associated with CPSS.

Keywords: congenital portosystemic shunt; hyperammonemia; sodium phenylbutyrate.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Amino Acids, Branched-Chain / blood
  • Ammonia / blood
  • Humans
  • Hyperammonemia / blood
  • Hyperammonemia / drug therapy*
  • Infant
  • Male
  • Phenylbutyrates / therapeutic use*
  • Portal System / abnormalities*
  • Portal Vein / abnormalities

Substances

  • Amino Acids, Branched-Chain
  • Phenylbutyrates
  • Ammonia
  • 4-phenylbutyric acid